Literature DB >> 28077045

Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia.

Allison R Butts1, Christina Carracedo Bachmeier2, Emily V Dressler3, Meng Liu3, Ann Cowden4, Jeff Talbert5, Val R Adams5.   

Abstract

Objective The objective of this study was to determine the clinical impact of time to antibiotic administration in adult inpatients who have hematologic malignancies and develop febrile neutropenia. Methods A retrospective chart review was conducted to screen for all febrile neutropenia events amongst adult hematologic malignancy patients between 1 January 2010 and 1 September 2014. All included patients were admitted to the hospital at the time of fever onset, having been admitted for a diagnosis other than febrile neutropenia. Descriptive statistics and logistic generalized estimated equations were used to analyze the data. Results Two hundred forty-four neutropenic fever events met inclusion criteria. Thirty-five events (14.34%) led to negative clinical outcomes (in-hospital mortality, intensive care unit transfer, or vasopressor requirement), with an in-house mortality rate of 7.4%. The time to antibiotics ranged from 10 min to 1495 min. The median time to antibiotics in the events that led to negative outcomes was 120 min compared to 102 min in the events that did not lead to the negative outcome ( p = 0.93). Conditional order sets were used to order empiric antibiotics in 176 events (72.1%) and significantly reduced time to antibiotics from 287 min to 143 min ( p = 0.0019). Conclusion Prolonged time to antibiotic administration in hematologic malignancy patients who develop neutropenic fever was not shown to be associated with negative clinical outcomes.

Entities:  

Keywords:  Neutropenic fever; empiric antibiotics; hematologic malignancy; infectious disease

Mesh:

Substances:

Year:  2017        PMID: 28077045     DOI: 10.1177/1078155216687150

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  7 in total

1.  Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.

Authors:  Lisa M Daniels; Urshila Durani; Jason N Barreto; John C O'Horo; Mustaqeem A Siddiqui; John G Park; Pritish K Tosh
Journal:  Support Care Cancer       Date:  2019-02-25       Impact factor: 3.603

2.  Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review.

Authors:  Christa Koenig; Christine Schneider; Jessica E Morgan; Roland A Ammann; Lillian Sung; Bob Phillips
Journal:  Support Care Cancer       Date:  2019-07-01       Impact factor: 3.603

3.  Relationship Between the Use of Preprinted Physician Orders for Hospital-Acquired Fever and Time to Blood Culture Collection: A Single-Center Retrospective Cross-Sectional Study.

Authors:  Taku Harada; Shintaro Kosaka; Juichi Hiroshige; Takashi Watari
Journal:  Int J Gen Med       Date:  2022-07-02

4.  Predictive Models of Fever, ICU Transfer, and Mortality in Hospitalized Patients With Neutropenia.

Authors:  Elizabeth A Gulleen; Mawulolo K Ameko; John E Ainsworth; Laura E Barnes; Christopher C Moore
Journal:  Crit Care Explor       Date:  2020-12-02

Review 5.  Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?

Authors:  Ralph Boccia; John Glaspy; Jeffrey Crawford; Matti Aapro
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

6.  Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.

Authors:  Fan Zhang; RuiXia LingHu; XingYang Zhan; Ruisheng Li; Fan Feng; Xudong Gao; Lei Zhao; Junlan Yang
Journal:  Oncotarget       Date:  2017-05-24

7.  Factors and Outcomes Related to the Use of Guideline-Recommended Antibiotics in Patients With Neutropenic Fever at the Uganda Cancer Institute.

Authors:  Elizabeth A Gulleen; Scott V Adams; Bickey H Chang; Lauren Falk; Riley Hazard; Johnblack Kabukye; Jackie Scala; Catherine Liu; Warren Phipps; Omoding Abrahams; Christopher C Moore
Journal:  Open Forum Infect Dis       Date:  2021-06-10       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.